The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Lewin, M., Carlesso, N., Tung, C.-H., Tang, X.-W., Cory, D., Scadden, D. T., & Weissleder, R. (2000) · Nature Biotechnology · doi:10.1038/74464 · Cited by 1,716
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment
Liu, Z., Chen, K., Davis, C., Sherlock, S., Cao, Q., Chen, X., & Dai, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1468 · Cited by 1,348
Tat-mediated delivery of heterologous proteins into cells.
Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., & Barsoum, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.664 · Cited by 1,225
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Cited by
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,836
New approaches and procedures for cancer treatment: Current perspectives
Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T. (2021) · SAGE Open Medicine · doi:10.1177/20503121211034366 · Cited by 1,597
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Small molecules attached to peptides can be internalized through this mechanism, whereas TAT-polymer conjugate can be taken up through energy-dependent endocytosis or macropinocytosis [18].”
BackgroundChen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., & Yan, D. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505212y · Cited by 716
Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Understanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform
Mandal, B., Bhattacharjee, H., Mittal, N., Sah, H., Balabathula, P., Thoma, L. A., & Wood, G. C. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.11.010 · Cited by 467
Khandel, P., Yadaw, R. K., Soni, D. K., Kanwar, L., & Shahi, S. K. (2018) · Journal of Nanostructure in Chemistry · doi:10.1007/s40097-018-0267-4 · Cited by 452
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy
Chaturvedi, V. K., Singh, A., Singh, V. K., & Singh, M. P. (2019) · Current Drug Metabolism · doi:10.2174/1389200219666180918111528 · Cited by 418
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationReversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor
Yin, Q., Shen, J., Zhang, Z., Yu, H., & Li, Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.011 · Cited by 365
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationPeetla, C., Vijayaraghavalu, S., & Labhasetwar, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.004 · Cited by 289
Synergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 262
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Self-citationTherapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationPan, L., Liu, J., He, Q., Wang, L., & Shi, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.040 · Cited by 252
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Self-citationRuttala, H. B., & Ko, Y. T. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.02.040 · Cited by 141
Yee Kuen, C., & Masarudin, M. J. (2022) · Molecules · doi:10.3390/molecules27020473 · Cited by 78
Li, X., Yang, X., Lin, Z., Wang, D., Mei, D., He, B., Wang, X., Wang, X., Zhang, Q., & Gao, W. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.018 · Cited by 56
A Review on Theranostics: An Approach to Targeted Diagnosis and Therapy
Shrivastava, S., Jain, S., Kumar, D., Soni, S. L., & Sharma, M. (2019) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v7i2.463 · Cited by 53
Higa, L. H., Jerez, H. E., de Farias, M. A., Portugal, R. V., Romero, E. L., & Morilla, M. J. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0437 · Cited by 35
Gupta, A., Kaur, C. D., Saraf, S., & Saraf, S. (2017) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2016.1147581 · Cited by 27
Metadata
- Authors
- Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 14
- Issue
- 3
- Pages
- 150-163
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2019633596
- Cited by
- 504
- References
- 114
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.